The Divine Comedy begins with the middle-aged poet Dante wandering alone through a dark forest, having lost his way on the "true path." Driven deeper by frightening creatures blocking his escape route, he spies a human form that reveals itself to be the ghostly embodiment of the great Roman poet Virgil. Virgil offers to serve as Dante's guide out of the dark forest to Heaven but warns him that to get there they must first pass through Hell and Purgatory. Trusting his guide, Dante sets forth. What follows is a pilgrimage unlike any other recounted in Western literature, and Dante finds himself fundamentally changed forever.
Despite their ongoing financial successes, the big pharmaceutical companies have got to feel a bit like Dante at the beginning of a tough journey. Frightening creatures appear on an almost daily basis: A dwindling pipeline of potential new blockbuster drugs, endless news reports about excessive drug prices, competition from generics, stunning liability judgments, and demands for greater transparency in clinical trial data continue to push big pharma deeper into a dark forest of public approbation. The creatures are dangerous: within the last few weeks, Merck and Company announced plans to close five manufacturing plants, three research laboratories, and to lay off 11% of its work force (Berenson, 2005) . There is little empathy to be found in this world, as a recent Kaiser Family Foundation Health Poll Survey lists pharma's public approval rating at an all time low, although still more favorable than that of big oil and tobacco companies (Kaiser Family Foundation Health Poll Report Survey, 2005) .
There is an abundance of literature examining what precipitated this dramatic fall into the darkness of distrust. But the current negative press is nothing compared to the problems that big pharma will encounter unless it addresses its current predicament. Pharma faces a trip through Hell and Purgatory before a better future is realized, but it must first find a trustworthy guide to get it there.
A Virgil for Pharma
There are many would-be Virgils vying for the attention and resources of big pharma, but only one resumé stands out. In the postgenomics era, the ability to unravel the mechanisms of disease in the context of the entire human organism through the marriage of basic and clinical research is within our grasp. Focused scientific research is the Virgil that offers the best hope for pharma to find its way into a new future.
Many may argue that pharma isn't about scientific research per se but about the application of such research.
Although that may have been true at a time when there was a limited possibility of fully understanding the molecular mechanisms of how drugs work, the current state of biomedical research renders this a false distinction. The recent lawsuits over the anti-inflammatory drug Vioxx reveal the bankruptcy of our understanding of-and, in the public's perception, pharma's lack of interest in-mechanisms of disease in the context of the whole organism (Waxman, 2005; Frazier, 2005) . The "bench" and the "clinic" are no longer sustainable as disparate areas of study, although many practitioners of one or the other have yet to fully appreciate that or figure out how to merge the two enterprises.
With the fully annotated human genome sequence available, an initial catalog of human genetic variation, amazing technological breakthroughs in whole genome studies, and growing insights from developmental biology, we have before us the ability to look deeply into human biology and elucidate complete mechanisms of disease. An increase in our understanding of disease mechanisms should lead to new therapeutic interventions, but only if these efforts are led by scientific research that is open, collaborative, focused, and determined.
In the spirit of Dante's quest, I think it is worth considering a few of the obstacles that big pharma faces on the journey ahead. Despite continuing financial success, many big pharmaceutical companies are facing an uncertain future. Merging basic and clinical research in a determined effort to fully elucidate the molecular mechanisms of disease and thus to develop effective drugs with fewer side effects is the tough journey ahead that big pharma needs to pursue to ensure a brighter future.
Hence, if the present world doth go astray,
In you the cause is, be it sought in you.
-Dante Alighieri, La Divina Commedia, Purgatorio, Canto XVI demons and flames, the primary theological definition of Hell is "loss." This deeper meaning goes to some of big pharma's major fears about what may happen should it follow the scientific Virgil. Three closely related fears are immediately apparent.
The first and most obvious of these is financial. Pharma is convinced that it is in the business of human health, yet it really serves two masters. Pharma's shareholders demand-and have traditionally received-high returns on their investments. They rapidly punish those companies, or at least their corporate leaders, that do anything to threaten those returns. We have seen recently that the patience of new investors has a short time frame, whereas scientific research by its very nature cannot guarantee any specific deadline. As a result of this tension between expectations and reality, pharma are struggling to keep the "pipeline" of new drugs filled-particularly the late pipeline containing drugs in late-phase clinical trials. But there are not enough new drugs under development to fill every late pipeline to the satisfaction of investors, and efforts to do so divert valuable resources and attention from the basic research that needs to be done to understand disease in its physiological environment and to discover potentially excellent new drugs with few side effects. A firm commitment to rigorous and necessary scientific research as the basis of future drug development may necessarily mean the loss of many current shareholders and the uncertainty regarding the arrival of more far-sighted investors.
A second major concern for pharma is that scientific research demands a high degree of transparency. Does it really cost $800 million or more (DiMasi et al., 2003) to discover and develop a new drug, and what exactly does that cost include? What are the data-all the data-that support a specific avenue of inquiry? Pharma enjoys a fairly impenetrable curtain of protection about these and related questions, but to engage the scientific world will require that this curtain be torn away. Indications of the peril of doing so can be seen in the fulminant reaction to Marcia Angell's analysis of drug development cost and other issues in her book "The Truth about Drug Companies" (Angell, 2004) . In her book, Angell cites studies by Public Citizen (Public Citizen, 2001 ) and the Alliance on Tuberculosis Drug Development (Global Alliance for TB Drug Development, 2001 ), concluding that the costs of drug development are not as high as pharma has suggested. Regardless of whether or not the analyses in the book are correct, the tone of the counterattack indicates that the cost of drug development is not an area that could readily become transparent, at least any time soon (PHRMA, 2004) .
A third fear goes to the very organizational structure of most pharmaceutical companies. There is a growing public perception that the amount of money spent on marketing a particular drug is out of proportion to the actual worth of the therapy being marketed, whether because of "just as good" but cheaper competitors or because the drug is targeted at "diseases" that are relatively benign. In an age where "blockbuster drugs" (a purely financial designation) reign, sales and marketing departments of pharma companies tend to be both large and to play a leading role in the directions a pharma company pursues. That will not change without a significant internal battle for the very soul of the company and will undoubtedly result in the loss of some traditional pharmaceutical jobs and a realignment of internal power, most of it coming to rest in the hands of the scientists who discover and develop the drugs.
Passing through the Purgatorio
Once pharma gets past the big casualties of the Inferno, there is still a need for a major realignment of what remains as pharma passes through the Purgatorio (the theological meaning of Purgatory being "Purification").
Understanding the molecular mechanisms of disease implies that "large markets" such as diabetes will be fractured into many smaller mechanism-based patient populations. Just as there is no one genetic mechanism underlying type 2 diabetes, there is no one drug for all patients with this illness. Not that there is an infinite number of smaller markets-evolution simply won't allow that much human variation-but there are more smaller markets than the single phenotype of many diseases would suggest. By its nature, this fragmentation of patient populations according to different mechanisms of disease will require a significant overhaul of regulatory approval procedures, "marketing," patient and physician education, the role of academia, and even the fundamental pharma business model.
As mechanistic understanding circumscribes patient numbers, it will become increasingly impossible to do large-scale clinical trials, because in many cases there will not be enough patients to fully enroll a traditional trial. On the positive side, understanding disease mechanisms should enable the use of smaller, better-focused clinical trials. But if pharma is unprepared to retool its drug development program, drug regulatory agencies such as the U.S. Food and Drug Administration are even less well prepared. Much has been made of the partnership between industry and government in shortening approval times for drugs. It is time to bring that partnership to a new level that rethinks the approval process and redirects resources to make it happen.
The sad lack of scientific understanding by the general public currently assists pharma in its very successful direct-to-consumer marketing through advertisements on television and in magazines. This method of marketing certainly has benefits, but as drugs and drug combinations become more mechanism-based, direct-to-consumer marketing makes little sense given the generally poor scientific understanding of the general public. Thus, a huge educational effort has to happen. And not just for the would-be consumers, but for the physicians who prescribe these drugs and need to understand clearly how they work. Physicians will soon be faced with a palette of therapeutic options that will require a clear understanding of the multiple molecular contributions to the disease of the patient in front of them. The huge resources devoted to the current marketing corps of pharma companies could be retooled into a true educational operation, but only with significant changes. These include rethinking the entire rewards system (with its unforgiving emphasis on making the numbers) with the goal of providing a real understanding of how these drugs work, who should receive them, and how to determine this. Pharma already claims for itself a leading partnership in healthcare delivery. This kind of effort would make that claim more solid, both in the public perception of the industry and in fact.
Pharma is already hearing the footsteps of academia, which is rushing to fill the growing void in pharma's pipeline of drugs in the early stages of discovery and even in development. Pharma may be yielding some of this ground but would do better to become an active partner with academia. This means not just licensing discoveries made at universities and research institutes but actively participating in the research under academic "rules." More than just "splitting tasks" based on respective traditional strengths, this strategy would allow academia and pharma to inform each other throughout the research and drug development process. Working together, academia and pharma will build "trust, mutual scientific respect, and concomitant scientific goals" (Chin-Dusting et al., 2005) . That said, academia has picked up a few bad habits from its industrial partners, particularly in the areas of intellectual property and competitiveness that actually impede progress in biomedical research (Krimsky, 2003) . It is time for academia to reclaim the scientific habits that are its foundation and that will ultimately benefit its industrial partners on the path to the development of more effective drugs with fewer side effects.
"Blockbuster drugs" can still be developed in an increasingly fragmented market, but they can't be the basis of a business model. Pharma companies can still be profitableperhaps not to the degree they have enjoyed so far-but still sufficiently so. However, given that pricing and profits necessarily will be transparent in this new world, pharma will have to transform its business model in the glare of public attention if it is going to not only survive but also thrive.
At the Doorstep of a Paradiso
If pharma emerges from its tough journey, it will undoubtedly look very different than it does now. It is impossible to say just how it will look, largely because this journey will not take place in isolation. Societal issues such as healthcare costs, access to medicines, and even the ethics of prolonging life, as filtered through elected bodies such as the U.S. Congress, will undoubtedly be as much a determinant of pharma's future as any changes it makes within. Yet the form that these external influences take will be determined in large part by how proactive pharma is in undertaking tough adjustments to realize a better future.
